Table of Contents Table of Contents
Previous Page  679 / 812 Next Page
Information
Show Menu
Previous Page 679 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S675

From a sample of 51 inpatients, 15 of them were diagnosed with

disorders of the spectrumof schizophrenia and other psychotic dis-

orders. Of the patients, 13.3% was treated with haloperidol, 26.7%

with olanzapine, 26.7% with risperidone although it was modi-

fied by paliperidone in mental health center, 6.7% with quetiapine,

6.7% with amisulpride, 13.3% with oral paliperidone and 13.3%

patients with intramuscular paliperidone. Of these, 40% are read-

mitted to hospital. Patients were readmitted due to ineffectiveness

and adverse effects of haloperidol, olanzapine, risperidone. 73.3% of

inpatients were treated with monotherapy. Of the patients, 26.7%

were treated with polytherapy, who received olanzapine, risperi-

done and amisulpride. It would be important to use psychoactive

substances that allow monotherapy to reduce adverse effects and

psychiatric re-hospitalization.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2003

EV1019

Effects of using psychotropic drugs in

the etiology and prevention of deviant

behavior

S. Ibrahimi

Albanian University, Psychology, Tirana, Albania

Objective

The objective of the article is to explore the main fea-

tures of the relationship between these components that produce

the effect in the etiology of deviant behavior.

Methods

The study is a comprehensive and comparative of data

in the pharmaco-epidemology groups of Mental Health Care and

Community Centers in Albania in 2014–2015. The methods used

are explorative, qualitative and epidemiologic as to the reports of

subjects and official data.

Results

The psychiatry of changing behavior is certainly a mile-

stone of the nowadays health. Data collected from a 6-month

follow-up of new cases of youth with an uncontrolled impulse and

a low ego resilience on a psychotropic prescription have given a

clear view of connection between the type of psychotropic drug

used and the level of reaction the drug has created in the prevention

of a further development of deviant behavior.

Conclusions

In the end of this approach, we could reach to con-

firm that the more the knowledge on the usage and effects of

psychotropic drugs, the better will be the preventive efforts to their

effects over the deviant behavior in the individual.

Keywords

Psychotropic; Deviant behavior; Ethiology;

Prevention; Adverse effect

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2004

EV1020

New models for research and

development in the treatment of

mental illness

J.N. Kjær

Aarhus University Hospital, 1 Department of Organic Psychiatric

Disorders and Emergency Ward, Risskov, Denmark

The pharmaceutical industry’s investments in research and devel-

opment of novel treatments for mental illness have heavily

declined in the past decade. Major private investments are, by

most experts, seen as necessary to develop new treatments. How-

ever, psychiatry is not the only area overlooked by the industry.

For decades infectious diseases have also lacked investments in

research and development.

Aims

The aims of this study were to investigate the new models

of research and development in infectious diseases that emerged

after the pharmaceutical industry ceased their investments and to

model how these can be used in psychiatry.

Method

A systematic review. We searched PubMed, EMBASE and

Web of Science for the keywords “infectious diseases”, “research

and development” and “pharmaceutical industry”.

Preliminary results

The searches gave a total of 248 references.

Among the findings, we want to highlight the Drugs for Neglected

Diseases initiative (DNDi) and the WHO Research and Develop-

ment Treaty (R&D Treaty). DNDi is a non-profit organization that

has developed six new drugs since 2003. The development costs

were

D

150 millions per drug, which is considerably belowthe costs

for drug development claimed by the pharmaceutical industry. The

R&D Treaty will commit member states of the WHO to fund devel-

opment for neglected health needs using alternative incentives like

milestone prizes, patent pools and direct grants. The treaty has not

yet been agreed upon.

Conclusions

Though a low priority from the pharmaceutical

industry, other funding models have proven able to deliver new

treatments. This could also lead to more development of non-

patentable treatments, e.g. psychotherapy.

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2005

EV1021

Clinical and socio-demographic

characteristics of a sample of

outpatients with long-acting

injectable antipsychotic treatment

J. Moreno Monmany

, I. Tinoco Calero , N. Bagué Gomez ,

B. Samsó Buxareu , V. Chavarria Romero , S. Castillo Maga˜na ,

S. Oller Canet

Parc de Salut Mar, INAD, Barcelona, Spain

Corresponding author.

Introduction

There are relatively few studies of Long-acting

injectable antipsychotics (LAI), although poor adherence to treat-

ment is one of the main problems in patients with psychotic

disorders.

Objectives

The aim of the study is to describe socio-demographic

and clinical characteristics of a sample of outpatientswith LAI treat-

ment.

Methods

This is a cross-sectional study. A randomized sam-

pling was performed among the outpatients that were receiving

LAI in an outpatient clinic in Barcelona (Spain). For each patient,

socio-demographic, clinical and pharmacotherapeutic data were

collected through interviews and clinical history.

Results

The sample consisted of 30 subjects (50% men, average

age 48 years). Most of the patients in the sample have basic edu-

cation (50%) and are unemployed, receiving permanent disability

pension (39.3%). In addition, 44.8% of the subjects were living with

family members and were not married (56.7%). Of the patients,

70%were diagnosed with schizophrenia, 13.3% schizoaffective, 10%

bipolar and 6.7% delusional disorder. Themain reason to initiate LAI

treatment was due to non-compliance of the prescribed oral treat-

ment (85.7%). The 40% of patients were also with oral antipsychotic

treatment. Average punctuation in the 3 first items of the Scale to

Assess Unawareness of Mental Disorder: 11. Average punctuation

in the short version of the Simpson-Angus Scale: 1.68.

Conclusions

In our sample, the outpatients with LAI treatment

had a low functioning and disease awareness. Although the main

reason to start LAI is the non-compliance, 40% of the patients were

concurrently treated with oral antipsychotics. The extrapyramidal

side effects are mild.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2006